Faster engraftment, less transfusions, and less severe mucositis with ID-PTCy than with HD-PTCy. (A-E) Results by treatment group are shown. (A-B) Day of neutrophil and platelet engraftment. (C-D) Numbers of red blood cell (RBC) and platelet transfusions in the first 30 days after HCT. Of note, transfusion thresholds for patients were 7 g/dL for hemoglobin and 10 × 10³/μL for platelets unless clinical circumstances required higher thresholds (eg, fever or bleeding). (E) Duration of mucositis (including oral, pharyngeal, and rectal) as graded by common terminology criteria for adverse events version 5.0. Patients who did not engraft were not included for panels A-E. (F) Donor myeloid (CD33⁺) and T-cell (CD3⁺) chimerism results for all patients. One patient in DL2 with early malignancy relapse had insufficient cells at day +28 for CD33⁺ bead-sorted chimerism but flow cytometrically sorted chimerism of CD14⁺ cells at day +22 had showed 99% donor chimerism, and that result is included for the day +28 timepoint. Otherwise, patients with peripheral blood counts insufficient to perform chimerism analyses were categorized as not reported (NR). ∗P<.05; ∗∗P<.01.